“The Dual Action”
A dual-receptor agonist, one step past standard GLP-1 drugs, targeting both appetite and insulin sensitivity for metabolic control.
Tirzepatide activates both the GIP and GLP-1 receptors, which together slow gastric emptying, reduce appetite, and improve insulin sensitivity. The dual mechanism is why it tends to outperform single-receptor GLP-1 drugs in trials.
Yes. It's approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).
It carries a full FDA-reviewed safety profile from large clinical trials, more data than almost anything else discussed in the peptide space.
Primarily gastrointestinal: nausea, diarrhea, and constipation are the most commonly reported, especially when starting or increasing dose.
Tirzepatide is one of the most rigorously studied metabolic peptides that exists, with multiple completed Phase 3 trials and years of real-world prescription use behind it.
The numbers are only half of it. The Blueprint covers exact dosing per peptide, proven stacks, and step-by-step injection instructions.
The complete peptide reference. 20+ compounds broken down, step-by-step instructions, stack breakdowns, troubleshooting, and a 30% sourcing discount code.
Learn More · $40